Cargando…
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma
The prognosis of patients suffering from glioblastoma [also referred to as glioblastoma multiforme (GBM)] is dismal despite multimodal therapy. Chemotherapy with temozolomide may suppress tumor growth for a certain period of time (a few months); however, invariable tumor recurrence suggests that gli...
Autores principales: | Cheng, Zhen-Xiu, Yin, Wen-Bo, Wang, Zhong-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627876/ https://www.ncbi.nlm.nih.gov/pubmed/28901390 http://dx.doi.org/10.3892/ijmm.2017.3124 |
Ejemplares similares
-
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype
por: Yan, Wei, et al.
Publicado: (2015) -
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
por: Tian, Tian, et al.
Publicado: (2016) -
MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT
por: Zhao, Chengbin, et al.
Publicado: (2020) -
MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor
por: Chen, Yan, et al.
Publicado: (2019) -
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
por: Stepanenko, Aleksei A., et al.
Publicado: (2016)